Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease
-
Socinski, Mark A. (Univeristy of Pittsburgh Cancer Institute)
;
Kaye, Frederic J. (University of Florida College of Medicine) ;
Spigel, David R. (Sarah Cannon Research Institute) ;
Kudrik, Fred J. (South Carolina Oncology Associates) ;
Ponce, Santiago (Hospital 12 de Octubre (Madrid)) ;
Ellis, Peter M. (Juravinski Cancer Centre) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Lorigan, Paul (University of Manchester/Christie NHS Foundation Trust) ;
Gandhi, Leena (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Gutierrez, Martin E. (Holy Cross Hospital) ;
Nepert, Dale (Clinical Development. ImmunoGen Inc) ;
Corral, Jesus (Hospital 12 de Octubre (Madrid)) ;
Ares, Luis Paz (Hospital 12 de Octubre (Madrid)) ;
Universitat Autònoma de Barcelona
Subscribe to this discussion. You will then receive all new comments by email.
guest ::
